CA3043610A1 - Crystalline forms of a magl inhibitor - Google Patents

Crystalline forms of a magl inhibitor Download PDF

Info

Publication number
CA3043610A1
CA3043610A1 CA3043610A CA3043610A CA3043610A1 CA 3043610 A1 CA3043610 A1 CA 3043610A1 CA 3043610 A CA3043610 A CA 3043610A CA 3043610 A CA3043610 A CA 3043610A CA 3043610 A1 CA3043610 A1 CA 3043610A1
Authority
CA
Canada
Prior art keywords
compound
crystalline form
theta
crystalline
hexafluoropropan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3043610A
Other languages
English (en)
French (fr)
Inventor
Cheryl A. Grice
Todd K. Jones
Kurt G. GRIMM
Jacqueline Lorayne BLANKMAN
Channing Rodney Beals
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
Abide Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abide Therapeutics Inc filed Critical Abide Therapeutics Inc
Publication of CA3043610A1 publication Critical patent/CA3043610A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA3043610A 2016-11-16 2017-11-15 Crystalline forms of a magl inhibitor Pending CA3043610A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662423126P 2016-11-16 2016-11-16
US62/423,126 2016-11-16
PCT/US2017/061875 WO2018093953A1 (en) 2016-11-16 2017-11-15 Crystalline forms of a magl inhibitor

Publications (1)

Publication Number Publication Date
CA3043610A1 true CA3043610A1 (en) 2018-05-24

Family

ID=62145805

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3043610A Pending CA3043610A1 (en) 2016-11-16 2017-11-15 Crystalline forms of a magl inhibitor

Country Status (38)

Country Link
US (2) US11142517B2 (cg-RX-API-DMAC7.html)
EP (2) EP3541807B1 (cg-RX-API-DMAC7.html)
JP (2) JP7042548B2 (cg-RX-API-DMAC7.html)
KR (1) KR102508739B1 (cg-RX-API-DMAC7.html)
CN (2) CN115093382A (cg-RX-API-DMAC7.html)
AU (1) AU2017361257B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019010003A2 (cg-RX-API-DMAC7.html)
CA (1) CA3043610A1 (cg-RX-API-DMAC7.html)
CL (1) CL2019001340A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019005045A2 (cg-RX-API-DMAC7.html)
CR (1) CR20190242A (cg-RX-API-DMAC7.html)
CY (2) CY1124870T1 (cg-RX-API-DMAC7.html)
DK (1) DK3541807T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2019000120A (cg-RX-API-DMAC7.html)
EA (1) EA201991086A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP19035171A (cg-RX-API-DMAC7.html)
ES (2) ES2966939T3 (cg-RX-API-DMAC7.html)
GE (2) GEP20237559B (cg-RX-API-DMAC7.html)
HR (2) HRP20231697T1 (cg-RX-API-DMAC7.html)
HU (2) HUE064559T2 (cg-RX-API-DMAC7.html)
IL (1) IL266548A (cg-RX-API-DMAC7.html)
JO (1) JOP20190109B1 (cg-RX-API-DMAC7.html)
LT (1) LT3541807T (cg-RX-API-DMAC7.html)
MA (2) MA46866B1 (cg-RX-API-DMAC7.html)
MX (2) MX389459B (cg-RX-API-DMAC7.html)
MY (1) MY199386A (cg-RX-API-DMAC7.html)
NI (1) NI201900053A (cg-RX-API-DMAC7.html)
PE (1) PE20191239A1 (cg-RX-API-DMAC7.html)
PH (1) PH12019501068A1 (cg-RX-API-DMAC7.html)
PL (2) PL3541807T3 (cg-RX-API-DMAC7.html)
PT (1) PT3541807T (cg-RX-API-DMAC7.html)
RS (2) RS62665B1 (cg-RX-API-DMAC7.html)
SI (1) SI3541807T1 (cg-RX-API-DMAC7.html)
SM (2) SMT202300494T1 (cg-RX-API-DMAC7.html)
TN (1) TN2019000151A1 (cg-RX-API-DMAC7.html)
UA (1) UA124585C2 (cg-RX-API-DMAC7.html)
WO (1) WO2018093953A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201903093B (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ627750A (en) 2012-01-06 2016-11-25 Abide Therapeutics Inc Carbamate compounds and of making and using same
US10450302B2 (en) 2015-05-11 2019-10-22 Lundbeck La Jolla Research Center, Inc. Methods of treating inflammation or neuropathic pain
CN109996790B (zh) 2016-09-19 2023-05-16 H.隆德贝克有限公司 哌嗪氨基甲酸酯及其制备和使用方法
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
PL3541807T3 (pl) 2016-11-16 2022-01-17 H. Lundbeck A/S Krystaliczna postać inhibitora magl
CA3043609A1 (en) 2016-11-16 2018-05-24 Abide Therapeutics, Inc. Pharmaceutical formulations
US10927105B1 (en) 2017-05-23 2021-02-23 Lundbeck La Jolla Research Center, Inc. Pyrazole MAGL inhibitors
MY200738A (en) 2017-05-23 2024-01-13 H Lundbeck As Pyrazole magl inhibitors
UA126685C2 (uk) 2017-08-29 2023-01-11 Луннбек Ла-Холья Рісьоч Сенте, Інк. Сполуки, які є модуляторами magl, і способи їх отримання і застосування
MA52635A (fr) * 2018-05-15 2021-03-24 H Lundbeck As Inhibiteurs de magl
CA3106510A1 (en) * 2018-07-19 2020-01-23 Pfizer Inc. Heterocyclic spiro compounds as magl inhibitors
MY210507A (en) 2018-08-13 2025-09-28 Hoffmann La Roche New heterocyclic compounds as monoacylglycerol lipase inhibitors
WO2020104494A1 (en) 2018-11-22 2020-05-28 F. Hoffmann-La Roche Ag New heterocyclic compounds
SG11202108008PA (en) * 2019-01-25 2021-08-30 H Lundbeck As Methods of treating disease with magl inhibitors
BR112021013917A2 (pt) * 2019-11-15 2022-05-24 H Lundbeck As Forma cristalina de um inibidor de magl, composição farmacêutica e uso
WO2021214550A1 (en) * 2020-04-21 2021-10-28 H. Lundbeck A/S Synthesis of a monoacylglycerol lipase inhibitor
WO2023092079A1 (en) * 2021-11-19 2023-05-25 Bryant Cynthia W Use of cannabinoid compounds to treat gastrointestinal disorders
IL313987A (en) 2021-12-29 2024-08-01 Psy Therapeutics Inc Inhibiting monoacylglycerol lipase (magl)
WO2023213854A1 (en) 2022-05-04 2023-11-09 H. Lundbeck A/S Crystalline form of 1,1,1,3,3,3-hexafluoropropan-2-yl (s)-1-(pyridazin-3-ylcarbamoyl)-6 azaspiro[2.5]octane-6-carboxylate as monoacylglycerol lipase inhibitor.
CN117665187B (zh) * 2023-11-23 2024-08-16 宁波大红鹰药业股份有限公司 一种舒林酸中间体杂质的测定方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
ES2111065T5 (es) 1991-04-16 2005-06-16 Nippon Shinyaku Company, Limited Procedimiento para producir una dispersion solida.
CZ282760B6 (cs) 1991-11-22 1997-09-17 Procter And Gamble Pharmaceuticals, Inc. Risedronátové prostředky se zpožděným uvolňováním
US5461140A (en) 1992-04-30 1995-10-24 Pharmaceutical Delivery Systems Bioerodible polymers for solid controlled release pharmaceutical compositions
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
WO1994008568A1 (fr) 1992-10-16 1994-04-28 Nippon Shinyaku Co., Ltd. Procede pour fabriquer des matrices de cire
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
KR19990014865A (ko) 1995-05-17 1999-02-25 피터 이. 브래이브맨 소장에서의 소화 및 흡수를 증진시키기 위한, 지방산을 함유한조성물들
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
AU2001225816B2 (en) 2000-12-18 2005-10-13 Novartis Ag Therapeutic combination of amlodipine and benazepril
US6465014B1 (en) 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
DE60325834D1 (de) 2002-02-20 2009-03-05 Abbott Lab Kondensierte azabicyclischeverbindungen als inhibitoren des vanilloid-rezeptors 1 (vr1)
US7074805B2 (en) 2002-02-20 2006-07-11 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
CA2598762A1 (en) 2005-02-25 2006-08-31 F. Hoffmann-La Roche Ag Tablets with improved drug substance dispersibility
ES2812250T3 (es) 2005-11-28 2021-03-16 Marinus Pharmaceuticals Inc Formulaciones de ganaxolona y procedimientos para la preparación y uso de las mismas
EP1938804A1 (en) 2006-12-22 2008-07-02 Novartis AG Pharmaceutical formulation comprising neurokinin antagonist
FR2938341A1 (fr) 2008-11-13 2010-05-14 Galderma Res & Dev Modulateurs de la monoglyceride lipase dans le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee
WO2010063802A1 (en) 2008-12-05 2010-06-10 Novartis Ag 3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists
CN101530399B (zh) 2009-04-15 2011-01-26 江苏中兴药业有限公司 一种水飞蓟宾固体自乳化片
NZ627750A (en) * 2012-01-06 2016-11-25 Abide Therapeutics Inc Carbamate compounds and of making and using same
EP2828253A1 (en) 2012-03-19 2015-01-28 Abide Therapeutics, Inc. Carbamate compounds and of making and using same
WO2013159095A1 (en) 2012-04-20 2013-10-24 Anderson Gaweco Ror modulators and their uses
KR102396897B1 (ko) 2012-11-02 2022-05-13 버텍스 파마슈티칼스 인코포레이티드 Cftr 매개된 질환의 치료를 위한 약제학적 조성물
TW201446286A (zh) 2013-01-31 2014-12-16 Gilead Pharmasset Llc 抗病毒化合物之固態分散調製劑
US9551036B2 (en) 2013-02-25 2017-01-24 Whitehead Institute For Biomedical Research Metabolic gene mesenchymal signatures and uses thereof
US9828379B2 (en) 2013-07-03 2017-11-28 Abide Therapeutics, Inc. Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof
WO2015030854A1 (en) 2013-08-27 2015-03-05 Gilead Pharmasset Llc Solid dispersion formulation of an antiviral compound
CN103893258B (zh) 2013-12-05 2017-09-29 人福医药集团股份公司 含有广金钱草总黄酮的口服固体制剂及其应用
WO2015164160A1 (en) 2014-04-21 2015-10-29 Merck Sharp & Dohme Corp. Pharmaceutical salts of an orexin receptor antagonist
WO2015179559A2 (en) 2014-05-21 2015-11-26 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
WO2016149401A2 (en) 2015-03-18 2016-09-22 Abide Therapeutics, Inc. Piperazine carbamates and methods of making and using same
US10450302B2 (en) 2015-05-11 2019-10-22 Lundbeck La Jolla Research Center, Inc. Methods of treating inflammation or neuropathic pain
US10463753B2 (en) * 2016-02-19 2019-11-05 Lundbeck La Jolla Research Center, Inc. Radiolabeled monoacylglycerol lipase occupancy probe
PL3541807T3 (pl) 2016-11-16 2022-01-17 H. Lundbeck A/S Krystaliczna postać inhibitora magl
JOP20190105A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
CA3043609A1 (en) 2016-11-16 2018-05-24 Abide Therapeutics, Inc. Pharmaceutical formulations
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190106A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)

Also Published As

Publication number Publication date
EP3541807A4 (en) 2020-04-22
SI3541807T1 (sl) 2022-01-31
PL3541807T3 (pl) 2022-01-17
EP3964503C0 (en) 2023-11-08
HRP20211863T1 (hr) 2022-03-04
CL2019001340A1 (es) 2019-10-04
JP2022084717A (ja) 2022-06-07
NI201900053A (es) 2019-10-30
MA46866A (fr) 2021-06-02
CN110291083B (zh) 2022-06-17
MX2022000249A (es) 2022-02-03
PE20191239A1 (es) 2019-09-16
DK3541807T3 (da) 2021-12-06
GEP20237559B (en) 2023-10-25
JP7042548B2 (ja) 2022-03-28
PT3541807T (pt) 2021-12-09
RS62665B1 (sr) 2021-12-31
US20220235037A1 (en) 2022-07-28
MA58133B1 (fr) 2024-02-29
MX389459B (es) 2025-03-20
EP3964503A1 (en) 2022-03-09
PL3964503T3 (pl) 2024-04-02
RU2019116689A3 (cg-RX-API-DMAC7.html) 2021-02-26
KR20190077561A (ko) 2019-07-03
AU2017361257B2 (en) 2022-02-10
EP3964503B1 (en) 2023-11-08
JP7350117B2 (ja) 2023-09-25
CY1124870T1 (el) 2022-11-25
GEAP202315091A (en) 2023-05-10
RS65016B1 (sr) 2024-01-31
PH12019501068A1 (en) 2019-08-19
CO2019005045A2 (es) 2019-05-31
EP3541807B1 (en) 2021-09-29
JOP20190109A1 (ar) 2019-05-09
HUE064559T2 (hu) 2024-03-28
LT3541807T (lt) 2021-12-27
CN115093382A (zh) 2022-09-23
US20200190063A1 (en) 2020-06-18
UA124585C2 (uk) 2021-10-13
NZ753241A (en) 2021-06-25
ECSP19035171A (es) 2019-05-31
SMT202100675T1 (it) 2022-01-10
RU2019116689A (ru) 2020-12-17
US11993588B2 (en) 2024-05-28
US11142517B2 (en) 2021-10-12
ZA201903093B (en) 2020-11-25
CR20190242A (es) 2019-07-09
ES2900016T3 (es) 2022-03-15
MY199386A (en) 2023-10-25
EA201991086A1 (ru) 2019-11-29
MA46866B1 (fr) 2021-11-30
CN110291083A (zh) 2019-09-27
TN2019000151A1 (en) 2020-10-05
SMT202300494T1 (it) 2024-01-10
CY1126586T1 (el) 2026-02-25
IL266548A (en) 2019-07-31
JP2019537596A (ja) 2019-12-26
WO2018093953A1 (en) 2018-05-24
MX2019005767A (es) 2019-12-05
DOP2019000120A (es) 2019-09-30
BR112019010003A2 (pt) 2019-08-20
ES2966939T3 (es) 2024-04-25
AU2017361257A1 (en) 2019-05-30
JOP20190109B1 (ar) 2022-09-15
HUE056973T2 (hu) 2022-04-28
HRP20231697T1 (hr) 2024-03-15
EP3541807A1 (en) 2019-09-25
KR102508739B1 (ko) 2023-03-09

Similar Documents

Publication Publication Date Title
US11993588B2 (en) Crystalline forms of a MAGL inhibitor
RS66922B1 (sr) Kristalni oblici metil (s)‑2‑((2‑(2,6-difluoro‑4‑(metilkarbamoil)fenil)‑7-metilimidazo[1,2-a]piridin‑3-il)metil)morfolin‑4-karboksilata modulatora p2x3
US9956201B2 (en) Compositions comprising bioreversible derivatives of hydroxy N-substituted-2-aminotetralins, and related dosage forms
US10426724B2 (en) Antihistamine compositions, combinations, and use thereof
AU2018325267B2 (en) Crystalline forms of compounds for preventing or treating sensory hair cell death
HK40069310A (en) A crystalline form of a magl inhibitor
HK40069310B (en) A crystalline form of a magl inhibitor
RU2799564C2 (ru) Кристаллические формы ингибитора magl
HK40009165A (en) A crystalline form of a magl inhibitor
HK40009165B (en) A crystalline form of a magl inhibitor
WO2024011142A1 (en) Crystalline forms of an s1p receptor modulator
EA041551B1 (ru) Кристаллические формы ингибитора magl
NZ753241B2 (en) Crystalline forms of a magl inhibitor
WO2026085383A1 (en) Crystalline forms of an nlrp3 modulator
EP4551576A1 (en) Crystalline forms of a tyk2 inhibitor
WO2017073738A1 (ja) フェキソフェナジンを有効成分とする錠剤

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220921

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251111

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260106

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260107